201 related articles for article (PubMed ID: 34027794)
1. Homeobox A5 activates p53 pathway to inhibit proliferation and promote apoptosis of adrenocortical carcinoma cells by inducing Aldo-Keto reductase family 1 member B10 expression.
Chen D; Shen Z; Cheng X; Wang Q; Zhou J; Ren F; Sun Y; Wang H; Huang R
Bioengineered; 2021 Dec; 12(1):1964-1975. PubMed ID: 34027794
[TBL] [Abstract][Full Text] [Related]
2. FNDC5 and AKR1B10 inhibit the proliferation and metastasis of adrenocortical carcinoma cells by regulating AMPK/mTOR pathway.
Chen D; Huang R; Ren F; Wang H; Wang C; Zhang Y
Exp Ther Med; 2023 Mar; 25(3):136. PubMed ID: 36845952
[TBL] [Abstract][Full Text] [Related]
3. [Aldo-keto reductase family 1 B10 participates in the regulation of hepatoma cell cycle through p27/p-Rb signaling pathway].
Geng N; Jin YY; Zhu SX; Li YR; Zheng LY; Zhu WJ; Li YW; Han C; Dou XG; Bai H
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):861-867. PubMed ID: 33105932
[No Abstract] [Full Text] [Related]
4. AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis.
Ohashi T; Idogawa M; Sasaki Y; Suzuki H; Tokino T
Mol Cancer Res; 2013 Dec; 11(12):1554-63. PubMed ID: 24140838
[TBL] [Abstract][Full Text] [Related]
5. The expression and significance of AKR1B10 in laryngeal squamous cell carcinoma.
Liu J; Ban H; Liu Y; Ni J
Sci Rep; 2021 Sep; 11(1):18228. PubMed ID: 34521883
[TBL] [Abstract][Full Text] [Related]
6. Loss of AKR1B10 promotes colorectal cancer cells proliferation and migration via regulating FGF1-dependent pathway.
Yao Y; Wang X; Zhou D; Li H; Qian H; Zhang J; Jiang L; Wang B; Lin Q; Zhu X
Aging (Albany NY); 2020 Jul; 12(13):13059-13075. PubMed ID: 32615540
[TBL] [Abstract][Full Text] [Related]
7. HOXA5 inhibits the proliferation of extrahepatic cholangiocarcinoma cells by enhancing MXD1 expression and activating the p53 pathway.
Xiong F; Liu W; Wang X; Wu G; Wang Q; Guo T; Huang W; Wang B; Chen Y
Cell Death Dis; 2022 Sep; 13(9):829. PubMed ID: 36167790
[TBL] [Abstract][Full Text] [Related]
8. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Yan R; Zu X; Ma J; Liu Z; Adeyanju M; Cao D
Int J Cancer; 2007 Nov; 121(10):2301-6. PubMed ID: 17597105
[TBL] [Abstract][Full Text] [Related]
9. AKR1B10 inhibits the proliferation and migration of gastric cancer via regulating epithelial-mesenchymal transition.
Shao X; Wu J; Yu S; Zhou Y; Zhou C
Aging (Albany NY); 2021 Sep; 13(18):22298-22314. PubMed ID: 34552036
[TBL] [Abstract][Full Text] [Related]
10. Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
Li H; Yang AL; Chung YT; Zhang W; Liao J; Yang GY
Carcinogenesis; 2013 Sep; 34(9):2090-8. PubMed ID: 23689354
[TBL] [Abstract][Full Text] [Related]
11. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.
Liu R; Zheng S; Yang CY; Yu Y; Peng S; Ge Q; Lin Q; Li Q; Shi W; Shao Y
Medicine (Baltimore); 2021 Apr; 100(14):e25454. PubMed ID: 33832153
[TBL] [Abstract][Full Text] [Related]
13. CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling.
Huang Z; Yan Y; Zhu Z; Liu J; He X; Dalangood S; Li M; Tan M; Cai J; Tang P; Huang R; Shen B; Yan J
Cell Death Dis; 2021 May; 12(6):537. PubMed ID: 34035231
[TBL] [Abstract][Full Text] [Related]
14. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls.
Wang C; Yan R; Luo D; Watabe K; Liao DF; Cao D
J Biol Chem; 2009 Sep; 284(39):26742-8. PubMed ID: 19643728
[TBL] [Abstract][Full Text] [Related]
15. Structure and promoter characterization of aldo-keto reductase family 1 B10 gene.
Liu Z; Zhong L; Krishack PA; Robbins S; Cao JX; Zhao Y; Chung S; Cao D
Gene; 2009 May; 437(1-2):39-44. PubMed ID: 19236911
[TBL] [Abstract][Full Text] [Related]
16. AKR1B10 confers resistance to radiotherapy via FFA/TLR4/NF-κB axis in nasopharyngeal carcinoma.
Liu X; Hu Z; Qu J; Li J; Gong K; Wang L; Jiang J; Li X; He R; Duan L; Luo W; Xia C; Luo D
Int J Biol Sci; 2021; 17(3):756-767. PubMed ID: 33767586
[TBL] [Abstract][Full Text] [Related]
17. LncRNA HOTAIR participates in the development and progression of adrenocortical carcinoma via regulating cell cycle.
Yan ZC; He L; Qiu JH; Deng WT; Lu JR; Yuan Z; Liu DJ; Zheng RQ; Jiang W
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6640-6649. PubMed ID: 30402836
[TBL] [Abstract][Full Text] [Related]
18. Aldo-keto reductase family 1 member B10 is regulated by nucleos(t)ide analogues for chronic hepatitis B.
Orita N; Kawaguchi K; Honda M; Shimode T; Hayakawa N; Terashima T; Komura T; Nishikawa M; Horii R; Nio K; Shimakami T; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S; Kagaya T; Yamashita T
Biochem Biophys Res Commun; 2023 Sep; 674():133-139. PubMed ID: 37419034
[TBL] [Abstract][Full Text] [Related]
19. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
[TBL] [Abstract][Full Text] [Related]
20. [AKR1B10 promotes proliferation of breast cancer cells by activating Wnt/β-catenin pathway].
Qu J; Liu X; Li J; Gong K; Duan L; Luo W; Luo D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Dec; 35(12):1094-1100. PubMed ID: 31894008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
